Reexamining the research exemption

Article Abstract:

The extent to which biomedical research is subject to the patent laws continues to trouble scientists and decision makers in the pharmaceutical and biotech industries. However the court would adopt a rigid standard that can be applied with certainty to all situations, important issues such as the applicability of the FDA exemption to activities that infringe tool patents no doubt will remain unsettled.

Research and Development in the Physical, Engineering, and Life Sciences, Research and Testing Services, Medical Research, Epilepsy & Muscle Disease R&D, Administration of Public Health Programs, Health Research Programs, Medicine, Experimental

---

Negotiating the RNAi patent thicket

Article Abstract:

Merck of Whitehouse Station, New Jersey has acquired Sirna Therapeutics, which is focusing exclusively on RNA interference (RNAi), a method for turning genes off selectively using short double-stranded RNA molecules. The therapeutic value of RNAi is still unknown and delivering RNAi drugs to target cells is posing difficult challenges as the drug-development with RNAi is still in preclinical stages.

RNA interference

---

US courts struggle with new patent infringement standards

Article Abstract:

The United States court is facing the challenge of setting up new patent infringement standards and providing its conclusive interpretation of the law. District courts had applied the Fesco rules to biotech and pharmaceutical technology cases, but each court arrived at a different decision.

Product standards, safety, & recalls, Standards, Patent infringement

Similar abstracts:

• Abstracts: Funding the fleet. Managing the transition. Recognising performance
• Abstracts: A question of presentation. Inspiring confidence. Do the numbers make sense?
• Abstracts: Tightening the screw on tax planning. At a crossroads? The ghost of Christmas past
• Abstracts: Gamestec used ATEI to release new solutions. Getting sorted. Sega's two new games and one new website
• Abstracts: The changing attitude of European VCs. Next-generation monoclonals less profitable than trailblazers?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.